Renal complications of mitomycin C therapy with special reference to the total dose

Publisher Website
Google Scholar
Abstract
Patients (142) with gastrointestinal cancer were treated with combination chemotherapy containing mitomycin C. The mitomycin C dose was .ltoreq. 15 mg/m2 every 53rd day and the total cumulative dose was between 25-250 mg. Of the evaluable 118 patients 10 (8.5%) developed renal toxicity due to mitomycin C. Of these 10 patients 5 had microangiopathic hemolytic anemia as well. Six of them died 2-4.5 mo. after the last mitomycin C dose and 4 are alive 14-30 mo. after the last dose. Only 1 of the 63 patients (1.6%) who received < 50 mg/m2 mitomycin C developed renal toxicity. Of the 37 patients 4 (10.8%) who received 50-69 mg/m2 and 5 of 18 (27.8%) who received > 70 mg/m2 of mitomycin C developed nephrotoxicity. The toxicity of mitomycin C seem dose related, the safe total dose being < 50 mg/m2 if delivered in doses of 10 to 15 mg/m2 at 8-wk intervals.